David J. Allsup

Jan 2, 2025 | mdpi.com | David J. Allsup

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessReview by Stefano Molica 1,* and David Allsup 1,2 1Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull HU3 2JZ, UK 2Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK *Author to whom correspondence should be addressed.

Dec 11, 2023 | nejm.org | David Cairns |David J. Allsup |Kate Cwynarski |Andrew Pettitt

December 10, 2023 DOI: 10.1056/NEJMoa2310063 AbstractThe combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib–venetoclax and personalization of treatment duration according to measurable residual disease (MRD) is more effective than fludarabine–cyclophosphamide–rituximab (FCR) is unclear.